Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Sun Pharma Warns Taro Board Against Selling Irish Plant

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - India's Sun Pharmaceutical has warned the board of Israel's Taro Pharmaceutical to halt moves to sell a drug manufacturing unit in Ireland as the two firms dispute whether a year-old merger agreement remains in effect

You may also be interested in...



India’s Sun Pharma Begins Open Offer For Taro at $7.75

NEW DELHI - India's Sun Pharma said its Alkaloida Chemical unit started a tender offer for all shares of Israel's Taro Pharmaceutical as part of a disputed $460 million merger agreement reached a year ago, but unilaterally cancelled by Taro in late May

India’s Sun Pharma Begins Open Offer For Taro at $7.75

NEW DELHI - India's Sun Pharma said its Alkaloida Chemical unit started a tender offer for all shares of Israel's Taro Pharmaceutical as part of a disputed $460 million merger agreement reached a year ago, but unilaterally cancelled by Taro in late May

PharmAsia News Notable Notes: Citigroup Reiterates Buy On India’s Sun Pharma

NEW DELHI - Citigroup Global Markets reiterated its buy on Sun Pharma, India's largest drug company by market capitalization, saying a recent price dip related to a disputed merger attempt with Israel's Taro Pharma offers a "window of opportunity.

Related Content

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel